News
M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 17th Annual WORLDSymposium™ 2021
– Study Results Highlight Potential Utility of Targeting Mannose 6-Phosphate Pathway to Treat <a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div class=glossaryItemBody><!-- wp:paragraph -->Gaucher disease is a rare, autosomal ...
M6P Therapeutics Supports Rare Disease Day 2021 and Joins Global Movement to Increase Awareness of Rare Diseases
ST. LOUIS, Mo., – Feb. 25, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and <a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div ...
M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board
ST. LOUIS, Mo., – Feb. 3, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and <a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div ...
M6P Therapeutics Receives Six Rare Pediatric Disease Designations from the U.S. FDA for Company’s Deep Pipeline of Programs for Lysosomal Storage Disorders
– U.S. FDA Also Grants Two Orphan Drug Designations for the Company’s <a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div class=glossaryItemBody><!-- wp:paragraph -->A gene therapy is a therapeutic approach ...